Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma

[1]  Arthur James Cooper,et al.  Central Role of Glutamate Metabolism in the Maintenance of Nitrogen Homeostasis in Normal and Hyperammonemic Brain , 2016, Biomolecules.

[2]  Susan M. Chang,et al.  Magnetic resonance analysis of malignant transformation in recurrent glioma , 2016, Neuro-oncology.

[3]  Andrei I Holodny,et al.  Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. , 2016, Neuro-oncology.

[4]  Matthew C. Cave,et al.  Alcoholic Liver Disease: Update on the Role of Dietary Fat , 2016, Biomolecules.

[5]  P. Decker,et al.  IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas , 2015, Oncotarget.

[6]  J. Sherman,et al.  Current trends in the surgical management and treatment of adult glioblastoma. , 2015, Annals of translational medicine.

[7]  Jing Chen,et al.  Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation , 2015, Tumor Biology.

[8]  S. Nelson,et al.  Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells. , 2014, Cancer research.

[9]  P. Larson,et al.  Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma. , 2014, Cancer research.

[10]  Annette M Molinaro,et al.  Characterization of metabolites in infiltrating gliomas using ex vivo 1H high-resolution magic angle spinning spectroscopy , 2014, NMR in biomedicine.

[11]  C. Brennan,et al.  Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine , 2013, Oncotarget.

[12]  Daniel B Vigneron,et al.  Non-invasive in vivo assessment of IDH1 mutational status in glioma , 2013, Nature Communications.

[13]  Jason C. Crane,et al.  SIVIC: Open-Source, Standards-Based Software for DICOM MR Spectroscopy Workflows , 2013, Int. J. Biomed. Imaging.

[14]  Fang Wang,et al.  An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.

[15]  Susan M. Chang,et al.  Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging. , 2013, Neuro-oncology.

[16]  O. Abdel-Wahab,et al.  The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization* , 2012, The Journal of Biological Chemistry.

[17]  Steven Eschrich,et al.  The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. , 2012, Cancer research.

[18]  D. Backos,et al.  The role of glutathione in brain tumor drug resistance. , 2012, Biochemical pharmacology.

[19]  Hong Wu,et al.  Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy , 2012, Journal of Neuro-Oncology.

[20]  Mitchel S. Berger,et al.  Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas , 2012, Science Translational Medicine.

[21]  Ovidiu C. Andronesi,et al.  Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy , 2012, Science Translational Medicine.

[22]  S. Marie,et al.  Metabolism and Brain Cancer , 2011, Clinics.

[23]  Nuria Lopez-Bigas,et al.  Gitools: Analysis and Visualisation of Genomic Data Using Interactive Heat-Maps , 2011, PloS one.

[24]  K. Kinzler,et al.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome , 2011, Proceedings of the National Academy of Sciences.

[25]  K. Yen,et al.  Cancer-associated IDH mutations: biomarker and therapeutic opportunities , 2010, Oncogene.

[26]  John Kurhanewicz,et al.  Semi‐parametric time‐domain quantification of HR‐MAS data from prostate tissue , 2010, NMR in biomedicine.

[27]  Albert P. Chen,et al.  Implementation of 3 T Lactate-Edited 3D 1H MR Spectroscopic Imaging with Flyback Echo-Planar Readout for Gliomas Patients , 2010, Annals of Biomedical Engineering.

[28]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[29]  H. Zentgraf,et al.  Monoclonal antibody specific for IDH1 R132H mutation , 2009, Acta Neuropathologica.

[30]  Zenon Starčuk,et al.  Quantitation of magnetic resonance spectroscopy signals: the jMRUI software package , 2009 .

[31]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[32]  J. Kurhanewicz,et al.  Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR‐MAS spectroscopy of biopsy tissues , 2008, Magnetic resonance in medicine.

[33]  Susan M. Chang,et al.  Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. , 2005, AJNR. American journal of neuroradiology.

[34]  Susan M. Chang,et al.  Dynamic susceptibility contrast perfusion imaging of radiation effects in normal‐appearing brain tissue: Changes in the first‐pass and recirculation phases , 2005, Journal of magnetic resonance imaging : JMRI.

[35]  Edward J. Dropcho,et al.  Low-grade gliomas in adults , 2004, Current treatment options in neurology.

[36]  E. R. Andrew,et al.  Nuclear Magnetic Resonance Spectra from a Crystal rotated at High Speed , 1958, Nature.

[37]  S. Meiboom,et al.  Modified Spin‐Echo Method for Measuring Nuclear Relaxation Times , 1958 .

[38]  N. Voets,et al.  Non-invasive quantification of 2-hydroxyglutarate in human gliomas with IDH 1 and IDH 2 mutations , 2017 .

[39]  Peter Jezzard,et al.  Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations. , 2016, Cancer research.

[40]  M. Berger,et al.  Survival and low-grade glioma: the emergence of genetic information. , 2015, Neurosurgical focus.

[41]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[42]  J. Uhm.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .

[43]  G. Reifenberger,et al.  Molecular neuropathology of low-grade gliomas and its clinical impact. , 2010, Advances and technical standards in neurosurgery.

[44]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[45]  Daniel Rueckert,et al.  VTK CISG Registration Toolkit: An Open Source Software Package for Affine and Nonrigid Registration of Single- and Multimodal 3D images , 2002, Bildverarbeitung für die Medizin.

[46]  P. Basser,et al.  Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. , 1996, Journal of magnetic resonance. Series B.